Trials / Completed
CompletedNCT02389972
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 128 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to describe the effectiveness of dasatinib (Sprycel®) in CML patients in China in the real-world clinical practice setting.
Detailed description
Breakpoint cluster region (BCR) Abelson murine leukemia viral oncogene homolog 1 (c-ABL) Chronic myeloid leukemia (CML)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib |
Timeline
- Start date
- 2013-04-11
- Primary completion
- 2017-07-13
- Completion
- 2017-07-13
- First posted
- 2015-03-17
- Last updated
- 2017-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02389972. Inclusion in this directory is not an endorsement.